State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
School of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
J Zhejiang Univ Sci B. 2020 May;21(5):343-360. doi: 10.1631/jzus.B2000083. Epub 2020 May 8.
Pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection emerged in Wuhan City, Hubei Province, China in December 2019. By Feb. 11, 2020, the World Health Organization (WHO) officially named the disease resulting from infection with SARS-CoV-2 as coronavirus disease 2019 (COVID-19). COVID-19 represents a spectrum of clinical manifestations that typically include fever, dry cough, and fatigue, often with pulmonary involvement. SARS-CoV-2 is highly contagious and most individuals within the population at large are susceptible to infection. Wild animal hosts and infected patients are currently the main sources of disease which is transmitted via respiratory droplets and direct contact. Since the outbreak, the Chinese government and scientific community have acted rapidly to identify the causative agent and promptly shared the viral gene sequence, and have carried out measures to contain the epidemic. Meanwhile, recent research has revealed critical aspects of SARS-CoV-2 biology and disease pathogenesis; other studies have focused on epidemiology, clinical features, diagnosis, management, as well as drug and vaccine development. This review aims to summarize the latest research findings and to provide expert consensus. We will also share ongoing efforts and experience in China, which may provide insight on how to contain the epidemic and improve our understanding of this emerging infectious disease, together with updated guidance for prevention, control, and critical management of this pandemic.
2019 年 12 月,中国湖北省武汉市出现了由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染引起的肺炎。截至 2020 年 2 月 11 日,世界卫生组织(WHO)正式将 SARS-CoV-2 感染所致疾病命名为 2019 冠状病毒病(COVID-19)。COVID-19 代表了一系列临床症状,通常包括发热、干咳和疲劳,常伴有肺部受累。SARS-CoV-2 具有高度传染性,人群中大多数个体易受感染。野生动物宿主和感染患者是目前疾病的主要传染源,通过呼吸道飞沫和直接接触传播。自疫情爆发以来,中国政府和科学界迅速行动,鉴定病原体并及时共享病毒基因序列,并采取措施控制疫情。同时,最近的研究揭示了 SARS-CoV-2 生物学和疾病发病机制的关键方面;其他研究则侧重于流行病学、临床特征、诊断、管理以及药物和疫苗开发。本综述旨在总结最新的研究发现,并提供专家共识。我们还将分享中国正在进行的努力和经验,这些经验可能有助于了解如何控制疫情并提高我们对这种新发传染病的认识,同时为大流行的预防、控制和关键管理提供最新指导。